Compare Merck & Co., Inc. (MRK) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.22 (market cap $4.35B). The key difference: Merck & Co., Inc. is far larger — about 80.8× State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF for 41 Days on average.
| MRK | SJNK | |
|---|---|---|
Market Cap | $351.28B | $4.35B |
Volume | 7,969,665 | 3,211,044 |
Sector | Health | Fixed Income |
52-Week High | $156.43 | $25.57 |
52-Week Low | $82.49 | $24.13 |
Typical Hold Time | 98 Days | 41 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
SJNK (SPDR Bloomberg Short Term High Yield Bond ETF) trades at $24.20, down 0.21% with a bearish technical outlook. The ETF shows strong institutional interest despite recent selling activity by some firms. Dividend distributions remain consistent with recent payments of $0.14-$0.15 per share, providing income appeal in a rising rate environment.
The ETF faces headwinds from technical weakness but maintains income appeal through consistent dividends. Key risks include interest rate sensitivity and institutional selling pressure, while the current yield advantage over Treasuries presents opportunity for income-focused investors in the high-yield bond space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
